Literature DB >> 10939285

Characterisation of kynurenine pathway metabolism in human astrocytes and implications in neuropathogenesis.

G J Guillemin1, D G Smith, S J Kerr, G A Smythe, V Kapoor, P J Armati, B J Brew.   

Abstract

The role of astrocytes in the production of the neurotoxin quinolinic acid (QUIN) and other products of the kynurenine pathway (KP) is controversial. Using cytokine-stimulated human astrocytes, we assayed key enzymes and products of the KP. We found that astrocytes lack kynurenine-hydroxylase so that large amounts of kynurenine (KYN) and kynurenic acid (KYNA) were produced, while minor amounts of QUIN were synthesised that were completely degraded. We then showed that kynurenine added to macrophages led to significant production of QUIN. These results suggest that astrocytes alone are neuroprotective by minimising QUIN production and maximising synthesis of KYNA. However, it is likely that, in the presence of macrophages and/or microglia, astrocytes are neurotoxic by producing large concentrations of KYN that can be metabolised by neighbouring monocytic cells to QUIN.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10939285     DOI: 10.1179/135100000101535375

Source DB:  PubMed          Journal:  Redox Rep        ISSN: 1351-0002            Impact factor:   4.412


  37 in total

1.  Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis.

Authors:  K Rejdak; A Petzold; T Kocki; J Kurzepa; P Grieb; W A Turski; Z Stelmasiak
Journal:  J Neural Transm (Vienna)       Date:  2007-03-29       Impact factor: 3.575

Review 2.  The role of the kynurenine metabolism in major depression.

Authors:  Aye-Mu Myint; Markus J Schwarz; Norbert Müller
Journal:  J Neural Transm (Vienna)       Date:  2011-12-03       Impact factor: 3.575

3.  Kynurenine pathway metabolites in humans: disease and healthy States.

Authors:  Yiquan Chen; Gilles J Guillemin
Journal:  Int J Tryptophan Res       Date:  2009-01-08

4.  Fluctuations in endogenous kynurenic acid control hippocampal glutamate and memory.

Authors:  Ana Pocivavsek; Hui-Qiu Wu; Michelle C Potter; Greg I Elmer; Roberto Pellicciari; Robert Schwarcz
Journal:  Neuropsychopharmacology       Date:  2011-07-27       Impact factor: 7.853

5.  The kynurenine pathway and inflammation in amyotrophic lateral sclerosis.

Authors:  Yiquan Chen; Roger Stankovic; Karen M Cullen; Vincent Meininger; Brett Garner; Sarah Coggan; Ross Grant; Bruce J Brew; Gilles J Guillemin
Journal:  Neurotox Res       Date:  2009-11-18       Impact factor: 3.911

Review 6.  The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression.

Authors:  Michael Maes; Raz Yirmyia; Jens Noraberg; Stefan Brene; Joe Hibbeln; Giulia Perini; Marta Kubera; Petr Bob; Bernard Lerer; Mario Maj
Journal:  Metab Brain Dis       Date:  2008-12-16       Impact factor: 3.584

7.  The vitamin-E analog trolox and the NMDA antagonist MK-801 protect pyramidal neurons in hippocampal slice cultures from IL-1beta-induced neurodegeneration.

Authors:  Ann-Cathrin Radesäter; Sara Johansson; Caroline Oberg; Johan Luthman
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

Review 8.  The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia.

Authors:  María Isabel Cuartero; Juan de la Parra; Alicia García-Culebras; Iván Ballesteros; Ignacio Lizasoain; María Ángeles Moro
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 9.  IDO and TDO as a potential therapeutic target in different types of depression.

Authors:  Yanjie Qin; Nanxi Wang; Xinlin Zhang; Xuemei Han; Xuejia Zhai; Yongning Lu
Journal:  Metab Brain Dis       Date:  2018-07-16       Impact factor: 3.584

Review 10.  Neuropsychiatric disorders related to interferon and interleukins treatment.

Authors:  Aye Mu Myint; Markus J Schwarz; Harry W M Steinbusch; Brian E Leonard
Journal:  Metab Brain Dis       Date:  2008-12-10       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.